Levicept

CompanyUnited Kingdom

Levicept develops one asset, in phase 2 (LEVI-04 in arthritis). Mostly protein or enzyme acting on NTF3; based in the United Kingdom.

1
Asset
Furthest stage
Phase 2
2
Trials
1
Signal

Pipeline

1
  • LEVI-04

    Soluble neurotrophin receptor fusion protein that binds neurotrophin-3 to reduce pain signaling.

    Phase 2, Protein or enzyme, NTF3, arthritis, joint diseases

Full company profiles: pipeline, trials, funding and people.

See Pro

In the full profile

  • Evidence behind the mechanisms1
  • Trials2
  • Signals2
  • Similar companies6

Intelligence